[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:actionable-genomic-alteration":3},{"name":4,"total":5,"recruiting":5,"trials":6},"actionable genomic alteration",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06332755","Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC",[11],"Phase 1","RECRUITING","2026-08-26T02:19:26.493949Z","2026-05-05T02:43:28.726792Z"]